Shock! Biotech raises money
Monday, 30 March, 2009
Melbourne stem cell company Mesoblast has raised $10.81 million through a private placement to existing as well as new and institutional investors.
The money will be used to further the company’s clinical trial programs, including its bone and cartilage regenerative products.
Mesoblast said the placement of 15.02 million shares was oversubscribed.
The money will come as a boost to the company’s cash reserves, which were $9.6 million as at December 31, 2008.
Inhaled form of blood thinner treats serious COVID infections
Heparin has traditionally been injected and used to treat blood clots, but the new study tested...
Next-gen therapies could treat high-grade gliomas
Government funding will enable researchers to test a suite of next-generation therapies they have...
Bacteriophage cocktail to combat superbugs
Entelli-02 is a five-phage cocktail designed specifically to target Enterobacter cloacae...
